Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 10, 2004. The report details a share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests related to the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 430,000 Ordinary shares.
- Purchase Price: 1,147.16 pence per share.
- Total Treasury Holdings: 19,649,000 shares following the transaction.
- Shares in Issue: 5,913,906,493 (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 430,000 shares on June 8, 2004, which are now held in Treasury. Additionally, the filing reports several transfers of shares from the GSK Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991, with the most recent transaction occurring on June 8, 2004 (3,171 shares).
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed beyond the standard disclosure of director interests in the employee trust.
Key Facts for Investor Verification
- Verify the total cost of the 430,000 share repurchase against the reported price of 1,147.16 pence per share.
- Confirm the updated total share count (5,913,906,493 in issue) against subsequent filings to ensure accuracy of the capital structure.
- Review the cumulative impact of the GSK Trust share transfers on the dilution or concentration of ownership among directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe.
- Note that this filing is a regulatory disclosure of specific transactions and does not replace quarterly or annual financial reports.